[1] Chintagumpala M, Gajjar A. Brain tumors[J]. Pediatr Clin North Am, 2015,62(1):167-178. [2] Khatua S, Song A, Sridhar D C, et al. Childhood medulloblastoma:current therapies, emerging molecular landscape and newer therapeutic insights[J]. Curr Neuropharmacol, 2018,16(7):1045-1058. [3] 武万水,杜淑旭,任思其,等. 采用HIT-2000方案治疗的41例髓母细胞瘤患儿疗效分析[J]. 中华实用儿科临床杂志, 2017,32(3):191-194. [4] Koschmann C, Bloom K, Upadhyaya S, et al. Survival after relapse of medulloblastoma[J]. J Pediatr Hematol Oncol, 2016,38(4):269-273. [5] Schroder K, Hertzog P J, Ravasi T, et al. Interferon-gamma:an overview of signals, mechanisms and functions[J]. J Leukoc Biol, 2004,75(2):163-189. [6] Lebrec H, Ponce R, Preston B D, et al. Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk[J]. Curr Med Res Opin, 2015,31(3):557-574. [7] Du S, Yang S, Zhao X, et al. Clinical characteristics and outcome of children with relapsed medulloblastoma:a retrospective study at a single center in China[J]. J Pediatr Hematol Oncol, 2018,40(8):598-604. [8] Bautista F, Fioravantti V, de Rojas T, et al. Medulloblastoma in children and adolescents:a systematic review of contemporary phase I and Ⅱ clinical trials and biology update[J]. Cancer Med, 2017,6(11):2606-2624. [9] Ardestani S, Li B, Deskins D L, et al. Membrane versus soluble isoforms of TNF-α exert opposing effects on tumor growth and survival of tumor-associated myeloid cells[J]. Cancer Res, 2013,73(13):3938-3950. [10] Mikami S L, Mizuno R, Kosaka T, et al. Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas[J]. Int J Cancer, 2015,136(7):1504-1514. [11] Jaime-Pérez J C, Gamboa-Alonso C M, Jiménez-Castillo R A, et al. TNF-α increases in the CSF of children with acute lymphoblastic leukemia before CNS relapse[J]. Blood Cells Mol Dis, 2017,63:27-31. [12] Peng Z, Ying L. Effects of TNFα on cell viability, proliferation and apoptosis of glioma cells U251[J]. J Buon, 2014,19(3):733-741. [13] Xu H W, Huang Y J, Xie Z Y, et al. The expression of cytoglobin as a prognostic factor in gliomas:a retrospective analysis of 88 patients[J]. BMC Cancer, 2013,13(1):247-247. [14] Lin S M, Lin C J, Hsu C W, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors[J]. Cancer,2004,100(2):376-382. [15] Wiegering V, Eyrich M, Rutkowski S, et al. TH1 predominance is associated with improved survival in pediatric medulloblastoma patients[J]. Cancer Immunol Immunother, 2011,60(5):693-703. [16] Sandén E, Enríquez Pérez J, Visse E, et al. Preoperative systemic levels of VEGFA, IL-7, IL-17A,and TNF-β delineate two distinct groups of children with brain tumors[J]. Pediatr Blood Cancer,2016,63(12):2112-2122. [17] Sabel M, Fleischhack G, Tippelt S, et al. Relapse patterns and outcome after relapse in standard risk medulloblastoma:a report from the HIT-SIOP-PNET4 study[J]. J Neurooncol, 2016,129(3):515-524. [18] 赵倩, 金眉,张大伟,等.4例同期治疗中进展的儿童髓母细胞瘤临床分析及经验总结[J].首都医科大学学报,2017,38(6):925-929. |